Rutherford adds biomarker testing to improve the selection of best treatment for cancer patients

A partnership between Rutherford Health plc and OncoDNA, a genomic and theranostic company specialising in precision medicine, will provide Rutherford cancer patients with access to the latest biomarker testing. The partnership will support the accessibility and development of the tests in the UK.

Comprehensive biomarker tests on solid and liquid biopsies help oncologists identify the most effective therapy for patients, as well as monitor disease progression and therapeutic response.

The collaboration will allow cancer patients who are eligible to access a more tailored approach to their treatment, supporting better clinical outcomes.

Rutherford Health plc ceo Mike Moran said: “This partnership will be key in bringing a personalised approach to our patients’ treatments. Doctors will now be able to offer treatments that are best suited to the genetic and genomic characteristics of the tumour.

“This partnership will help Rutherford’s extensive network of oncologists build their understanding of the latest genomic technology within the clinical setting, building confidence and an evidence base for continued use.”

OncoDEEP is a biomarker test that delivers deep analysis of a tumour tissue and matches it with the most efficient cancer treatments. OncoSELECT is a fast and minimally invasive liquid biopsy test that screens for cancer-specific biomarkers in blood or other fluids.

Picture: Rutherford Health’s independent network currently consists of four cancer treatment centres in Newport, Reading, Bedlington and Liverpool.

See the full report on page 8 of the September 2021 issue of RAD Magazine.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more